Mechanisms responsible for inhibition of lymphocyte activation by agents which block membrane calcium or potassium channels.
Weir
M R
MR
Department of Medicine, University of Maryland School of Medicine, Baltimore.
Gomolka
D
D
Peppler
R
R
Handwerger
B S
BS
D015761:4-Aminopyridine / Q000494:pharmacology*; D000328:Adult; D002118:Calcium / Q000378:metabolism*; D015220:Calcium Channels / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004261:DNA Replication / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics; D007930:Leucine / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D010835:Phytohemagglutinins / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects*; D012413:Rubidium / Q000378:metabolism; D013237:Stereoisomerism; D013936:Thymidine / Q000378:metabolism; D014529:Uridine / Q000378:metabolism; D014700:Verapamil / Q000494:pharmacology*
D015220:Calcium Channels; D007376:Interleukin-2; D010835:Phytohemagglutinins; D015221:Potassium Channels; D015761:4-Aminopyridine; D014700:Verapamil; D007930:Leucine; D012413:Rubidium; D002118:Calcium; D013936:Thymidine; D014529:Uridine